Remove Drug Development Remove Small Molecule Remove Virus
article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation small molecules. However, the advanced nature of the drugs being developed has brought new challenges. The global market for CNS therapeutics was worth an estimated $144.3

article thumbnail

Looking beyond traditional oncogenic pathways to break cancer resistance

Drug Target Review

However, this will not be straightforward, given that non-oncogene resistance is driven by complex transcriptional networks, and the key drivers that determine how these mechanisms could be targets for drug development remain elusive. This orally available small molecule binds to the bromodomain of CBP/p300 in a highly specific manner.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GPU-Accelerated Molecular Dynamics Applications Help Fight COVID-19

Nvidia Developer: Drug Discovery

To help make the process for scientists more accessible, we’re spotlighting a few of the GPU-accelerated applications that developers can use right now in the fight against this virus. Molecular dynamics simulations offer accurate approximations of real molecular behavior, which is useful in different stages of drug development.

article thumbnail

Fighting Parasitic Infections: Promise in Cyclic Peptides

NIH Director's Blog: Drug Discovery

But parasites are another important source of devastating infection, especially in the developing world. Researchers soon began screening a chemical library and its more than 380,000 traditional drug candidates to find the right small-molecule inhibitor, the preferred compound in drug discovery. Nat Commun.

article thumbnail

Rare autoantibody diseases: an innovative targeted pathway

Drug Target Review

Antibodies protect us by attaching to molecules on those invaders (known as antigens) and triggering our body’s natural immune response to destroy them. Approximately three percent of the global population — 240 million people — experience autoantibody diseases, which occur when one’s own body attacks critical organs and tissues.

article thumbnail

Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19 Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States

The Pharma Data

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Importantly, the manufacturing process for our small molecule direct-acting antiviral allows us to produce AT-527 quickly and at scale.”.

RNA
article thumbnail

Emerging Trends in Antibiotic Development to Combat Resistance

DrugBank

This discovery represents a shift in how antibiotics are identified, showcasing the potential of AI to uncover entirely new drug classes. Developing Antimicrobial Peptides and Biomolecules In addition to traditional small-molecule antibiotics, researchers are exploring the potential of antimicrobial peptides (AMPs) and other biomolecules.